FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.
What happened
FDA inspected Ava Inc.'s drug manufacturing facility in Willowbrook, Illinois, from October 6 to October 21, 2025. Investigators found shared HPLC usernames and passwords, analyst administrator privileges, deleted GC sequences, FTIR audit-trail gaps, and trial injections where favorable results were reported while out-of-specification results were not investigated. FDA also found the quality unit did not adequately oversee testing and release.
What FDA found
Ava did not adequately control its laboratory computer systems: staff shared an HPLC username and password, analysts had administrator rights, and GC sequences were deleted.
21 CFR 211.68(b)Laboratory records did not include complete data from all tests; trial injections and less favorable or out-of-specification results were omitted.
21 CFR 211.194(a)The quality unit lacked the authority and oversight to approve or reject materials and products and did not investigate out-of-specification results.
21 CFR 211.22(a); 211.160(a),(b); 211.192API testing data were incomplete because trial-injection chromatograms were not saved or kept in official batch records.
Written procedures allowed trial injections that were not processed as raw data, conflicting with CGMP recordkeeping requirements.
21 CFR 211.160(b)
What FDA wants
FDA tells Ava to correct the violations promptly and provide comprehensive assessments, CAPA plans, independent data-integrity and OOS reviews, and a qualified consultant's help; the letter does not state a specific response deadline.
Who should pay attention
- drug companies using Ava as a contract manufacturer
- brands selling finished drugs or APIs tested at this site
- quality teams managing laboratory data integrity and OOS investigations
This is a summary. Read the original letter on fda.gov.